Total Payments
$2,759
2024 Payments
$13.27
Companies
31
Transactions
95
Medicare Patients
1,523
Medicare Billing
$252,646
Payment Breakdown by Category
Food & Beverage$1,769 (64.1%)
Travel$959.52 (34.8%)
Education$29.76 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,769 | 91 | 64.1% |
| Travel and Lodging | $959.52 | 2 | 34.8% |
| Education | $29.76 | 2 | 1.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| LivaNova USA, Inc. | $1,213 | 7 | $0 (2018) |
| Supernus Pharmaceuticals, Inc. | $235.75 | 15 | $0 (2022) |
| ABBVIE INC. | $174.63 | 6 | $0 (2024) |
| Amgen Inc. | $142.57 | 11 | $0 (2018) |
| UCB, Inc. | $112.87 | 5 | $0 (2018) |
| Biogen, Inc. | $98.87 | 6 | $0 (2018) |
| GENZYME CORPORATION | $98.40 | 3 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $85.19 | 5 | $0 (2018) |
| Celgene Corporation | $80.72 | 4 | $0 (2023) |
| Allergan, Inc. | $63.66 | 4 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13.27 | 1 | ABBVIE INC. ($13.27) |
| 2023 | $109.96 | 7 | Celgene Corporation ($80.72) |
| 2022 | $47.57 | 3 | Allergan, Inc. ($19.63) |
| 2021 | $39.23 | 3 | Biohaven Pharmaceuticals, Inc. ($22.47) |
| 2020 | $47.71 | 3 | E.R. Squibb & Sons, L.L.C. ($29.76) |
| 2018 | $1,907 | 43 | LivaNova USA, Inc. ($1,213) |
| 2017 | $593.84 | 35 | Supernus Pharmaceuticals, Inc. ($153.84) |
All Payment Transactions
95 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | ABBVIE INC. | BOTOX (Biological), QULIPTA | Food and Beverage | In-kind items and services | $13.27 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/20/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.22 | General |
| Category: NEUROSCIENCE | ||||||
| 09/05/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $22.42 | General |
| Category: Neuroscience | ||||||
| 07/24/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $20.38 | General |
| Category: Neuroscience | ||||||
| 05/09/2023 | Sumitomo Pharma America, Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $1.47 | General |
| Category: CNS | ||||||
| 04/10/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $15.82 | General |
| Category: Neuroscience | ||||||
| 03/30/2023 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $13.55 | General |
| 02/21/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $22.10 | General |
| Category: Neuroscience | ||||||
| 09/08/2022 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $12.22 | General |
| Category: EPILEPSY | ||||||
| 06/23/2022 | Supernus Pharmaceuticals, Inc. | — | Food and Beverage | Cash or cash equivalent | $15.72 | General |
| 01/24/2022 | Allergan, Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $19.63 | General |
| Category: HYPERHYDROSIS | ||||||
| 08/18/2021 | Bausch & Lomb, a division of Bausch Health US, LLC | INFUSE (Device) | Food and Beverage | In-kind items and services | $16.76 | General |
| Category: Ophthalmology | ||||||
| 03/23/2021 | Biohaven Pharmaceuticals, Inc. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $11.05 | General |
| Category: PRIMARY CARE | ||||||
| 01/18/2021 | Biohaven Pharmaceuticals, Inc. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $11.42 | General |
| Category: PRIMARY CARE | ||||||
| 12/04/2020 | Biohaven Pharmaceuticals, Inc. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $17.95 | General |
| Category: PRIMARY CARE | ||||||
| 08/27/2020 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Education | Cash or cash equivalent | $14.88 | General |
| Category: Neuroscience | ||||||
| 08/27/2020 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Education | Cash or cash equivalent | $14.88 | General |
| Category: Neuroscience | ||||||
| 06/26/2018 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $19.01 | General |
| Category: Neuroscience | ||||||
| 06/19/2018 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $15.73 | General |
| Category: Neuroscience | ||||||
| 06/19/2018 | Egalet US Inc | SPRIX (Drug) | Food and Beverage | In-kind items and services | $14.29 | General |
| Category: Pain Medicine | ||||||
| 06/15/2018 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $21.29 | General |
| Category: Neuroscience | ||||||
| 05/30/2018 | LivaNova USA, Inc. | VNS Therapy (Device) | Food and Beverage | In-kind items and services | $7.44 | General |
| Category: VNS Therapy (Product Class) | ||||||
| 05/30/2018 | LivaNova USA, Inc. | VNS Therapy (Device) | Food and Beverage | In-kind items and services | $3.18 | General |
| Category: VNS Therapy (Product Class) | ||||||
| 05/29/2018 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $20.48 | General |
| 05/24/2018 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $5.93 | General |
| Category: Neuroscience | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 318 | 6,561 | $161,753 | $58,367 |
| 2022 | 9 | 314 | 5,758 | $147,843 | $52,445 |
| 2021 | 9 | 449 | 7,336 | $188,359 | $71,566 |
| 2020 | 11 | 442 | 8,508 | $196,827 | $70,268 |
Total Patients
1,523
Total Services
28,163
Medicare Billing
$252,646
Procedure Codes
38
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 17 | 6,200 | $86,800 | $30,650 | 35.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 77 | 94 | $21,432 | $8,368 | 39.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 111 | 144 | $23,040 | $7,748 | 33.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 26 | 28 | $8,932 | $3,585 | 40.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 28 | 28 | $8,260 | $3,231 | 39.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 23 | 23 | $4,508 | $1,846 | 40.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $4,279 | $1,731 | 40.4% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Office | 2023 | 11 | 19 | $3,116 | $744.23 | 23.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 14 | 14 | $1,386 | $464.41 | 33.5% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 11 | 5,400 | $75,600 | $26,040 | 34.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 88 | 110 | $25,014 | $9,031 | 36.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 122 | 151 | $24,076 | $8,827 | 36.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 25 | 25 | $7,375 | $2,750 | 37.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 19 | 22 | $6,961 | $2,435 | 35.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 11 | 11 | $4,279 | $1,731 | 40.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 11 | 11 | $2,156 | $664.99 | 30.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 15 | 15 | $1,485 | $510.82 | 34.4% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2022 | 12 | 13 | $897.00 | $455.30 | 50.8% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2021 | 15 | 6,800 | $95,200 | $32,710 | 34.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 124 | 163 | $31,785 | $14,339 | 45.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 153 | 195 | $25,740 | $11,754 | 45.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 35 | 40 | $10,480 | $4,618 | 44.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 40 | 40 | $12,000 | $4,499 | 37.5% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 27 | 27 | $5,265 | $1,905 | 36.2% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2021 | 25 | 27 | $1,863 | $888.78 | 47.7% |
About Dr. Thea Cross, M.D
Dr. Thea Cross, M.D is a Neurology healthcare provider based in Knoxville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1093788044.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thea Cross, M.D has received a total of $2,759 in payments from pharmaceutical and medical device companies, with $13.27 received in 2024. These payments were reported across 95 transactions from 31 companies. The most common payment nature is "Food and Beverage" ($1,769).
As a Medicare-enrolled provider, Cross has provided services to 1,523 Medicare beneficiaries, totaling 28,163 services with total Medicare billing of $252,646. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Knoxville, TN
- Active Since 02/09/2006
- Last Updated 02/07/2023
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1093788044
Products in Payments
- VNS Therapy (Device) $1,213
- TROKENDI XR (Drug) $220.03
- Duopa (Drug) $147.14
- ZEPOSIA (Drug) $110.48
- Vimpat (Drug) $94.82
- Aimovig (Biological) $61.96
- LUMIZYME (Drug) $59.35
- GILENYA (Drug) $49.21
- Fycompa (Drug) $47.08
- TECFIDERA (Drug) $44.56
- NURTEC ODT (Drug) $40.42
- LEMTRADA (Drug) $39.05
- ZINBRYTA (Biological) $38.44
- Reveal LINQ (Device) $35.61
- BOTOX (Biological) $32.90
- ACTHAR (Biological) $32.71
- BOTOX THERAPEUTIC (Biological) $30.85
- SPRIX (Drug) $28.58
- XEOMIN (Biological) $27.75
- SOLIRIS (Drug) $23.21
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Knoxville
Sibyl Wray, Md, MD
Neurology — Payments: $3.1M
Neurology $3.1M
Dr. David Brandes, Md, MD
Neurology — Payments: $1.1M
Neurology $1.1M
Randall Trudell, M.d, M.D
Neurology — Payments: $152,917
Neurology $152,917
Michelle Brewer, M.d, M.D
Neurology — Payments: $127,026
Neurology $127,026
Dr. Rosanne Barker, Md, MD
Neurology — Payments: $28,703
Neurology $28,703
Dr. Samir Al-Kabbani, Md, MD
Neurology — Payments: $23,480
Neurology $23,480